While the effects of adjunct incretin‐based therapy on overall glucose control, glycemic variability, risks of hypoglycemia, hyperglycemia, ketosis, and ketoacidosis largely depend on background beta‐cell reserve, T1D duration, background insulin treatment, and overall disease‐management capabilities, weight loss is a steadier result to be achieved and is not associated with insulin reserve. Here, INS is linked to type 1 diabetes mellitus.